NCT06940037 The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults
| NCT ID | NCT06940037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-08-11 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-08-11 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
Eligibility Criteria
Inclusion Criteria: * aged greater than or equal to 65 years * sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity * at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB * willing to be randomized into HE or PRT * willing to be transported or transport themselves to the clinical sites for the intervention and assessments Exclusion Criteria: * unwillingness to provide informed consent * participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months * an SPPB score of less than or equal to 3 * osteoarthritis or condition with joint pain limiting daily life activities * significant weight loss or gain (7.5% of body weight) in past six months * current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix) * clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the "normal limits', that are deemed to be of concern for participation in the study by the study physician * acute or terminal illness * Mini Mental State Exam (MMSE) \<23 * myocardial infarction in the previous 6 months or other symptomatic coronary artery disease * New York Heart Association Class III or IV congestive heart failure * serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG * chronic obstructive pulmonary disease requiring oxygen therapy * upper or lower extremity fracture in the previous 6 months * uncontrolled hypertension (150/90 mm Hg) * neuromuscular diseases and/or drugs which affect neuromuscular function * current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy * allergy to lidocaine * presence of significant liver or renal disease (eGFR \< 45 mL/min) * diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus * HbA1c \> 7% * BMI \<21 or \>35 for men or \>40 for women * excessive alcohol intake (\>14 alcoholic beverages per wk.) * current tobacco use * current participation in any interventional clinical trial * current use of weight loss medications
Contact & Investigator
Nathan LeBrasseur, Ph.D, MS
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06940037 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06940037 currently recruiting?
Yes, NCT06940037 is actively recruiting participants. Contact the research team at tweed.amanda@mayo.edu for enrollment information.
Where is the NCT06940037 trial being conducted?
This trial is being conducted at Boston, United States, Rochester, United States.
Who is sponsoring the NCT06940037 clinical trial?
NCT06940037 is sponsored by Mayo Clinic. The principal investigator is Nathan LeBrasseur, Ph.D, MS at Mayo Clinic. The trial plans to enroll 300 participants.